Published in J Immunol on February 01, 1997
The Effect of Omalizumab on Responses to Cat Allergen Challenge | NCT00604786
Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med (2011) 5.61
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
IgE and mast cells in allergic disease. Nat Med (2012) 3.14
Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation. J Allergy Clin Immunol (2013) 2.18
Future therapies for food allergies. J Allergy Clin Immunol (2011) 2.04
Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol (2009) 1.68
Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol (2007) 1.52
Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. J Allergy Clin Immunol (2014) 1.47
Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Invest (2010) 1.36
Basophils and allergic inflammation. J Allergy Clin Immunol (2013) 1.29
Basophil CD203c levels are increased at baseline and can be used to monitor omalizumab treatment in subjects with nut allergy. Int Arch Allergy Immunol (2010) 1.29
Beyond immediate hypersensitivity: evolving roles for IgE antibodies in immune homeostasis and allergic diseases. Immunol Rev (2011) 1.28
Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol (2009) 1.22
Complexity and redundancy in the pathogenesis of asthma: reassessing the roles of mast cells and T cells. J Exp Med (1997) 1.20
Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem (2010) 1.15
A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol (2013) 1.11
A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma. Ther Clin Risk Manag (2007) 1.11
Syk expression in peripheral blood leukocytes, CD34+ progenitors, and CD34-derived basophils. J Leukoc Biol (2009) 1.09
Anaphylactic cardiovascular collapse during hemodialysis: Kounis syndrome in the dialysis room. World J Cardiol (2014) 1.08
Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation. J Pharmacol Exp Ther (2007) 1.08
Peanut allergy: an overview. CMAJ (2003) 1.06
Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab. J Allergy Clin Immunol (2010) 1.04
Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc epsilonRI on human skin mast cells. J Immunol (2007) 1.02
Immunoglobulin E receptor signaling and asthma. J Biol Chem (2011) 1.02
Oral immunotherapy for food allergy: towards a new horizon. Allergy Asthma Immunol Res (2012) 0.98
The more allergens an atopic patient is exposed to, the easier and quicker anaphylactic shock and Kounis syndrome appear: Clinical and therapeutic paradoxes. J Nat Sci Biol Med (2014) 0.98
Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. Br J Clin Pharmacol (2011) 0.96
The Tec family kinase, IL-2-inducible T cell kinase, differentially controls mast cell responses. J Immunol (2008) 0.94
Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy (2014) 0.93
Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy. Int Arch Allergy Immunol (2009) 0.92
Saturation of immunoglobulin E (IgE) binding sites by polyclonal IgE does not explain the protective effect of helminth infections against atopy. Infect Immun (2005) 0.92
IgE-dependent signaling as a therapeutic target for allergies. Trends Pharmacol Sci (2012) 0.92
Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol (2013) 0.89
Immunoglobulin E plays an immunoregulatory role in lupus. J Exp Med (2014) 0.88
Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy (2007) 0.88
Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells. Cell Mol Immunol (2015) 0.88
Biologics in asthma--the next step toward personalized treatment. J Allergy Clin Immunol Pract (2015) 0.88
Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab. Clin Mol Allergy (2011) 0.87
Severe asthma: anti-IgE or anti-IL-5? Eur Clin Respir J (2016) 0.86
Anti-immunoglobulin E antibody treatment blocks histamine release and tissue contraction in sensitized mice. Immunology (1998) 0.86
Anaphylaxis: a history with emphasis on food allergy. Immunol Rev (2011) 0.84
How safe are the biologicals in treating asthma and rhinitis? Allergy Asthma Clin Immunol (2009) 0.84
The future of food allergy therapeutics. Semin Immunopathol (2012) 0.84
A long term case series study of the effect of omalizumab on chronic spontaneous urticaria. Ann Dermatol (2013) 0.84
Assessing basophil functional measures during monoclonal anti-IgE therapy. J Immunol Methods (2012) 0.84
Immunological mechanisms for desensitization and tolerance in food allergy. Semin Immunopathol (2012) 0.83
Long-term benefits of omalizumab in a patient with severe non-allergic asthma. Allergy Asthma Clin Immunol (2011) 0.83
Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J Allergy Clin Immunol (2016) 0.82
Omalizumab: a monoclonal anti-IgE antibody. MedGenMed (2005) 0.82
The role of omalizumab in the treatment of severe allergic asthma. Can Respir J (2006) 0.81
New insights into basophil heterogeneity. Semin Immunopathol (2016) 0.81
Severe asthma and the omalizumab option. Clin Mol Allergy (2008) 0.80
A Human Platelet Receptor Protein Microarray Identifies the High Affinity Immunoglobulin E Receptor Subunit α (FcεR1α) as an Activating Platelet Endothelium Aggregation Receptor 1 (PEAR1) Ligand. Mol Cell Proteomics (2015) 0.79
Novel targeted therapies for eosinophil-associated diseases and allergy. Annu Rev Pharmacol Toxicol (2014) 0.78
Harnessing the helminth secretome for therapeutic immunomodulators. Biomed Res Int (2014) 0.78
Structure of the omalizumab Fab. Acta Crystallogr F Struct Biol Commun (2015) 0.78
Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria. J Allergy Clin Immunol Pract (2015) 0.78
Omalizumab in the management of patients with allergic (IgE-mediated) asthma. J Asthma Allergy (2009) 0.78
Structural and Physical Basis for Anti-IgE Therapy. Sci Rep (2015) 0.78
Surface and gene expression of immunoglobulin E receptors on mast cells and mast-cell numbers in interleukin-4-gene knockout mice. Immunology (1999) 0.78
Effects of omalizumab on T lymphocyte function in inner-city children with asthma. Pediatr Allergy Immunol (2016) 0.78
A review of omalizumab for the management of severe asthma. Drug Des Devel Ther (2016) 0.76
The Potential of Anti-IgE in Food Allergy Therapy. Curr Treat Options Allergy (2014) 0.76
Control and regulation of peripheral tolerance in allergic inflammatory disease: therapeutic consequences. Chem Immunol Allergy (2008) 0.76
Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nat Commun (2016) 0.76
Improving the safety of oral immunotherapy for food allergy. Pediatr Allergy Immunol (2015) 0.76
Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies. MAbs (2013) 0.76
Mechanistic Correlates of Clinical Responses to Omalizumab in the Setting of Oral Immunotherapy for Milk Allergy. J Allergy Clin Immunol (2017) 0.76
Allergen Valency, Dose, and FcεRI Occupancy Set Thresholds for Secretory Responses to Pen a 1 and Motivate Design of Hypoallergens. J Immunol (2016) 0.75
Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin. Theranostics (2017) 0.75
Differences in effects of omalizumab on late-phase responses to allergen challenge in the skin and nose at the time of basophil hyporesponsiveness. J Invest Dermatol (2013) 0.75
The discovery of IgE 50 years later. Ann Allergy Asthma Immunol (2016) 0.75
Asthma and therapeutics: recombinant therapies in asthma. Allergy Asthma Clin Immunol (2005) 0.75
Cytomegalic hepatitis in a patient receiving omalizumab. IDCases (2016) 0.75
Roles for the High Affinity IgE Receptor, FcεRI, of Human Basophils in the Pathogenesis and Therapy of Allergic Asthma: Disease Promotion, Protection or Both? Open Allergy J (2010) 0.75
Profile of omalizumab in the treatment of chronic spontaneous urticaria. Drug Des Devel Ther (2015) 0.75
Is there a role for treatment of asthma with omalizumab? Arch Dis Child (2003) 0.75
Targeted IgE Therapy for Patients With Moderate to Severe Asthma. Biotechnol Healthc (2004) 0.75
Skewed Exposure to Environmental Antigens Complements Hygiene Hypothesis in Explaining the Rise of Allergy. Acta Biotheor (2017) 0.75
Relevance of allergy in adult asthma. Curr Allergy Asthma Rep (2014) 0.75
Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential. Ther Adv Chronic Dis (2016) 0.75
Omalizumab in Severe Refractory Vernal Keratoconjunctivitis in Children: Case Series and Review of the Literature. Ophthalmol Ther (2016) 0.75
Clinical course of rhinitis and changes in vivo and in vitro of allergic parameters in elderly patients: a long-term follow-up study. Clin Exp Med (2012) 0.75
Anti-IgE Treatment for Disorders Other Than Asthma. Front Med (Lausanne) (2017) 0.75
Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy (2017) 0.75
FceRI density and spontaneous secretion from human basophils. PLoS One (2017) 0.75
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med (1997) 5.48
Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science (1968) 4.38
Modulation of inflammation and immunity by cyclic AMP. Science (1974) 4.31
The role of cyclic 3',5' adenosine monophosphate in the specific cytolytic activity of lymphocytes. J Immunol (1972) 3.51
IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol (1992) 2.89
Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med (1991) 2.76
Pharmacologic control of allergic histamine release in vitro: evidence for an inhibitory role of 3',5'-adenosine monophosphate in human leukocytes. J Immunol (1972) 2.70
A reappraisal of sting challenges: to whom should we offer venom immunotherapy? J Allergy Clin Immunol (1994) 2.65
Inadequate outpatient medical therapy for patients with asthma admitted to two urban hospitals. Am J Med (1996) 2.59
A genome-wide association study on African-ancestry populations for asthma. J Allergy Clin Immunol (2009) 2.53
Anaphylaxis. N Engl J Med (1991) 2.53
Histamine augments leukocyte adenosine 3',5'-monophosphate and blocks antigenic histamine release. Science (1971) 2.47
Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol (2001) 2.38
Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis (1983) 2.37
Airway hyperresponsiveness in asthma: a problem of limited smooth muscle relaxation with inspiration. J Clin Invest (1995) 2.36
The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med (1990) 2.35
A case for venom treatment in anaphylactic sensitivity to hymenoptera sting. N Engl J Med (1974) 2.33
Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest (1998) 2.28
Inhibition of histamine release by histamine controlled by H2 receptor. Nature (1973) 2.19
Adult onset grape hypersensitivity causing life threatening anaphylaxis. Ann Allergy Asthma Immunol (1999) 2.18
IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol (1995) 2.18
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Immunological aspects of allergic asthma. Annu Rev Immunol (1994) 2.17
Effects of cholera enterotoxin on adenosine 3',5'-monophosphate and neutrophil function. Comparison with other compounds which stimulate leukocyte adenyl cyclase. J Clin Invest (1973) 2.16
Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol (1996) 2.13
Immediate hypersensitivity reactions to beta-lactam antibiotics. Ann Intern Med (1987) 2.11
A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med (1978) 2.08
Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol (2000) 2.05
Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest (1983) 2.05
A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma. Clin Immunol (1999) 2.04
Socioeconomic status and race as risk factors for cockroach allergen exposure and sensitization in children with asthma. J Allergy Clin Immunol (1996) 2.03
The effects of the H1 and H2 antihistamines on "allergic" histamine release and its inhibition by histamine. J Pharmacol Exp Ther (1975) 2.02
Histamine release from human leukocytes: studies with deuterium oxide, colchicine, and cytochalasin B. J Clin Invest (1972) 1.98
Molecular identification of an IgE-dependent histamine-releasing factor. Science (1995) 1.95
Effects of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3',5'-monophosphate. J Clin Invest (1973) 1.94
The immediate allergic response: in vitro separation of antigen activation, decay and histamine release. J Immunol (1971) 1.93
Ethnic differences in asthma and associated phenotypes: collaborative study on the genetics of asthma. J Allergy Clin Immunol (2001) 1.89
Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med (1985) 1.84
Clinical and in vitro studies on the role of immunotherapy in ragweed hay fever. Am J Med (1968) 1.84
Epidemiology of insect venom sensitivity. JAMA (1989) 1.83
Immunologic and cellular changes accompanying the therapy of pollen allergy. J Clin Invest (1971) 1.80
Human lung mast cells: purification and characterization. J Immunol (1982) 1.78
The role of cyclic AMP in the cytolytic activity of lymphocytes. J Immunol (1971) 1.78
Generation of leukotrienes by purified human lung mast cells. J Clin Invest (1982) 1.77
The immediate allergic response: in vitro action of cyclic AMP-active and other drugs on the two stages of histamine release. J Immunol (1971) 1.73
House dust mite and cockroach exposure are strong risk factors for positive allergy skin test responses in the Childhood Asthma Management Program. J Allergy Clin Immunol (2001) 1.73
Release of slow reacting substance of anaphylaxis (SRS-A) from human leukocytes by the calcium ionophore A23187. J Immunol (1976) 1.72
IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest (1978) 1.71
IgE responses in human filariasis. I. Quantitation of filaria-specific IgE. J Immunol (1981) 1.71
Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol (1996) 1.71
Asthma severity, atopic status, allergen exposure and quality of life in elderly persons. Ann Allergy Asthma Immunol (2001) 1.70
Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy (2008) 1.70
Basophil "releasability" in patients with asthma. Am Rev Respir Dis (1980) 1.70
IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol (1995) 1.68
The effects of a series of prostaglandins on in vitro models of the allergic response and cellular immunity. Prostaglandins (1972) 1.67
Physiologic manifestations of human anaphylaxis. J Clin Invest (1980) 1.65
Humanization of an antibody directed against IgE. J Immunol (1993) 1.64
Studies on the mechanism of lymphocyte-mediated cytolysis. IV. Specificity of the histamine receptor on effector T cells. J Immunol (1973) 1.63
Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy (2001) 1.63
Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA (2000) 1.62
IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest (1973) 1.58
Routine use of penicillin skin testing on an inpatient service. N Engl J Med (1971) 1.58
Potent bronchoprotective effect of deep inspiration and its absence in asthma. J Appl Physiol (1985) (2000) 1.56
Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol (1997) 1.55
Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther (2000) 1.54
Identification of basophil granulocytes as a site of allergic histamine release. J Immunol (1972) 1.52
In vitro studies of human reaginic allergy. Adv Immunol (1968) 1.50
Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol (1992) 1.48
Latex allergy: low prevalence of immunoglobulin E to highly purified proteins Hev b 2 and Hev b 13. Clin Exp Allergy (2007) 1.47
Arachidonic acid metabolism in purified human lung mast cells. J Immunol (1984) 1.47
Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease. Clin Exp Allergy (2009) 1.46
Antigen-specific IgE and IgA antibodies in bronchoalveolar lavage fluid are associated with stronger antigen-induced late phase reactions. Clin Exp Allergy (2001) 1.46
Subcutaneous allergen immunotherapy restores human dendritic cell innate immune function. Clin Exp Allergy (2010) 1.46
Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils. J Allergy Clin Immunol (2000) 1.46
Allergy to insect stings. II. Phospholipase A: the major allergen in honeybee venom. J Allergy Clin Immunol (1976) 1.45
The mechanism of basophil histamine release induced by antigen and by the calcium ionophore A23187. J Immunol (1975) 1.45
Nasal challenge with cold, dry air results in release of inflammatory mediators. Possible mast cell involvement. J Clin Invest (1985) 1.45
Episodic eosinophilia-myalgia-like syndrome in a patient without L-tryptophan use: association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. J Allergy Clin Immunol (1991) 1.45
Secretion of IL-4 from human basophils. The relationship between IL-4 mRNA and protein in resting and stimulated basophils. J Immunol (1994) 1.44
Prevalence of latex allergy among anesthesiologists: identification of sensitized but asymptomatic individuals. Anesthesiology (1998) 1.44
Kinins are generated during experimental rhinovirus colds. J Infect Dis (1988) 1.44
Properties of a subpopulation of T cells bearing histamine receptors. J Clin Invest (1975) 1.43
Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. Am Rev Respir Dis (1988) 1.43
Immunotherapy of pollinosis in children: investigation of the immunologic basis of clinical improvement. N Engl J Med (1969) 1.42
Studies on the mechanism of hypersensitivity phenomena. XI. The effect of normal human serum on the release of histamine from human leukocytes by ragweed pollen antigen. J Immunol (1966) 1.41
Cutaneous late-phase response in food-allergic children and adolescents with atopic dermatitis. Clin Exp Allergy (1993) 1.41
Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. J Clin Invest (1983) 1.41
Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis (1990) 1.40
Platelet activation during antigen-induced airway reactions in asthmatic subjects. N Engl J Med (1981) 1.40
Induction of histamine secretion by polycations. Biochim Biophys Acta (1980) 1.39
Eosinophil transendothelial migration induced by cytokines. I. Role of endothelial and eosinophil adhesion molecules in IL-1 beta-induced transendothelial migration. J Immunol (1992) 1.38
The lack of the bronchoprotective and not the bronchodilatory ability of deep inspiration is associated with airway hyperresponsiveness. Am J Respir Crit Care Med (2001) 1.38
Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am Rev Respir Dis (1991) 1.38